Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04496362 · ClinicalTrials.gov registry record · Phase 4
Veno-venous Extracorporeal Membrane Oxygenation (VV-ECMO) Heparin Study
A Phase 4 study of Respiratory Failure and ECMO, sponsored by Baylor Research Institute.
- Active
- Registry status
- Phase 4
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT04496362: Active Phase 4 study of Respiratory Failure and ECMO, sponsored by Baylor Research Institute.
NCT04496362 is a Phase 4 study of Respiratory Failure and ECMO that is active but no longer recruiting, run by Baylor Research Institute. The registered enrollment target is 100 participants, below the 4,521-participant average among 40 other Respiratory Failure trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04496362, a Phase 4 study of Respiratory Failure and ECMO, is active but no longer recruiting, sponsored by Baylor Research Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
This single-center, open-label study will evaluate the safety and efficacy of subcutaneous heparin anticoagulation compared to the standard of care systemic intravenous anticoagulation during veno-venous extracorporeal membrane oxygenation for respiratory failure.
Primary Outcome
Safety will be assessed by incidence of bleeding complication (clinically apparent or need for blood transfusion without identified source)
Conditions Studied
Interventions
- DRUG subcutaneous heparin anticoagulation
Study Locations (1)
Texas
- Baylor Scott & White Health research institute - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2018-10-10 |
| Est. Completion | 2026-06 |
| Phase | Phase 4 |
What the registry record for NCT04496362 still lists
NCT04496362 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 4,521-participant average among 40 other Respiratory Failure trials with a reported enrollment target (98% lower).
The record links to 3 conditions, with Respiratory Failure appearing as the primary indexed condition, and to 1 intervention - of which subcutaneous heparin anticoagulation is the first listed.
NCT04496362 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT04496362 about?
NCT04496362 is a clinical study titled "Veno-venous Extracorporeal Membrane Oxygenation (VV-ECMO) Heparin Study". This single-center, open-label study will evaluate the safety and efficacy of subcutaneous heparin anticoagulation compared to the standard of care systemic intravenous anticoagulation during veno-venous extracorporeal membrane oxygenation for respiratory failure.
What is the current status of trial NCT04496362?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 100 participants. The study started on 2018-10-10. Estimated completion is 2026-06.
What conditions does trial NCT04496362 study?
This clinical trial studies the following conditions: Respiratory Failure, ECMO, Heparin.
What interventions are being tested in trial NCT04496362?
The interventions under investigation include: subcutaneous heparin anticoagulation (DRUG).
Who is sponsoring clinical trial NCT04496362?
This trial is sponsored by Baylor Research Institute, which has 180 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04496362 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Respiratory Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04496362's enrollment target sits among peer trials
100 25th of 40 higher than 14 of 40 other Respiratory Failure trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Respiratory Failure trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Inhaled Nitric Oxide by Oxygen Hood in Neonates
COMPLETED · Phase 4
-
Analgesia-First Sedation in Trauma Patients
RECRUITING · NA
-
Hospital Airway Resuscitation Trial
RECRUITING · NA
-
Supraglottic Airway for Resuscitation in Preemies
RECRUITING · NA
-
The Family Perspectives Project Pilot Trial
RECRUITING · NA
-
End-Tidal Oxygen for Intubation in the Emergency Department
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01048281 · 100 participants
Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma
- NCT01161199 · 100 participants
The Use of Leukapheresis to Support HIV Pathogenesis Studies
- NCT01327690 · 100 participants · Early Phase 1
Mental Health in Veterans and Families After Group Therapies
- NCT01730781 · 100 participants
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI